10x Genomics, Inc. (NASDAQ:TXG) Shares Purchased by Algert Global LLC

Algert Global LLC boosted its stake in 10x Genomics, Inc. (NASDAQ:TXG) by 214.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 370,958 shares of the company’s stock after acquiring an additional 252,994 shares during the period. Algert Global LLC owned 0.31% of 10x Genomics worth $8,376,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC raised its holdings in shares of 10x Genomics by 134.5% during the second quarter. Allspring Global Investments Holdings LLC now owns 1,637 shares of the company’s stock worth $32,000 after purchasing an additional 939 shares during the period. GAMMA Investing LLC grew its position in shares of 10x Genomics by 451.8% during the third quarter. GAMMA Investing LLC now owns 1,545 shares of the company’s stock worth $35,000 after acquiring an additional 1,265 shares during the last quarter. Capital Performance Advisors LLP bought a new position in shares of 10x Genomics during the third quarter worth about $35,000. First Horizon Advisors Inc. grew its position in shares of 10x Genomics by 74.1% during the second quarter. First Horizon Advisors Inc. now owns 1,898 shares of the company’s stock worth $37,000 after acquiring an additional 808 shares during the last quarter. Finally, Covestor Ltd grew its position in shares of 10x Genomics by 501.7% during the first quarter. Covestor Ltd now owns 1,047 shares of the company’s stock worth $39,000 after acquiring an additional 873 shares during the last quarter. 84.68% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

TXG has been the subject of a number of recent analyst reports. Morgan Stanley decreased their target price on shares of 10x Genomics from $50.00 to $46.00 and set an “overweight” rating for the company in a research report on Tuesday, August 13th. The Goldman Sachs Group decreased their target price on shares of 10x Genomics from $16.00 to $14.00 and set a “sell” rating for the company in a research report on Wednesday, October 30th. Barclays decreased their target price on shares of 10x Genomics from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. JPMorgan Chase & Co. decreased their target price on shares of 10x Genomics from $20.00 to $14.00 and set a “neutral” rating for the company in a research report on Wednesday, October 30th. Finally, Stephens reiterated an “overweight” rating and issued a $30.00 target price on shares of 10x Genomics in a research report on Thursday, October 10th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, 10x Genomics currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.19.

10x Genomics Trading Up 7.7 %

Shares of TXG stock opened at $14.31 on Friday. The stock’s fifty day simple moving average is $17.57 and its 200-day simple moving average is $19.93. The company has a market capitalization of $1.73 billion, a price-to-earnings ratio of -9.35 and a beta of 1.87. 10x Genomics, Inc. has a 1-year low of $12.95 and a 1-year high of $57.90.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings data on Tuesday, October 29th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.04. The firm had revenue of $151.65 million for the quarter, compared to analyst estimates of $158.84 million. 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%. The company’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.51) EPS. On average, sell-side analysts predict that 10x Genomics, Inc. will post -1.4 EPS for the current year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.